Plus therapeutics to showcase respect-lm phase 1 interim data for leptomeningeal metastases at the 2024 san antonio breast cancer symposium

Company to present respect-lm phase 1 trial data on rhenium ( 186 re) obisbemeda with a focus on treating leptomeningeal metastases (lm) in breast cancer patients austin, texas, dec. 04, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, will present data at the 2024 san antonio breast cancer symposium, december 10-13, 2024 in san antonio, texas. presentation: title   rhenium (186re) obisbemeda (rhenium nanoliposome,186rnl) for the treatment of leptomeningeal metastases (lm): update on phase 1 dose escalation (abstract number: sess-2271, presentation id: ps14-01)       presenter   andrew brenner, m.d.
pstv Ratings Summary
pstv Quant Ranking